RetinAI Medical is a Swiss company that supports eye care professionals and patients
throughout the medical examination process using Artificial Intelligence (AI). Our vision is
to foster the transition from reactive medicine to preventive medicine for high-impact diseases
such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.
We will achieve this goal by removing technological barriers between patients and clinicians and
by enabling high-throughput screening in the field of ophthalmology.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and deep
learning. We have a unique team of scientists working to fully realise the capabilities
of AI, and to integrate this technology into the next generation of medical devices. Meet the Team!
What we do
RetinAI offers software solutions to empower eye care professionals during the evaluation of eye scans.
At its core lies a unique, interactive medical report that highlights and quantifies the
location, size and severity of pathological biomarkers in OCT, Fundus and Angiography images.
Through our intuitive user interface, ophthalmologists can determine the state of a
patient and monitor the progress of a treatment with a high degree of confidence.